SCHEMBL30064708

SCHEMBL30064708

C[C@H](N)c1cc2cc(Cl)cc(F)c2[nH]c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 3/20 0.47
HRH4 Q9H3N8 6/20 0.40
GRIN2D O15399 2/20 0.33
GRIN3B O60391 2/20 0.33
GRIN1 Q05586 2/20 0.33
GRIN2A Q12879 2/20 0.33
GRIN2B Q13224 2/20 0.33
GRIN2C Q14957 2/20 0.33
GRIN3A Q8TCU5 2/20 0.33
PYGL P06737 1/20 0.33
PYGM P11217 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MPO P05164 3/20 0.32
TPO P07202 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17601436 1.00 IDH1 (0.47) IDH1HRH4GRIN2DGRIN3BGRIN1
SCHEMBL17601439 1.00 IDH1 (0.47) IDH1HRH4GRIN2DGRIN3BGRIN1
Hydrochloric Acid SCHEMBL17601109 0.99 IDH1 (0.47) IDH1HRH4GRIN2DGRIN3BGRIN1
Hydrochloric Acid SCHEMBL17601106 0.99 IDH1 (0.47) IDH1HRH4GRIN2DGRIN3BGRIN1
SCHEMBL21549766 0.88 IDH1 (0.49) IDH1HRH4GRIN2DGRIN3BGRIN1
SCHEMBL21734885 0.84 HRH4 (0.39) IDH1HRH4GRIN2DGRIN3BGRIN1
SCHEMBL22198970 0.76 HRH4 (0.45) IDH1HRH4GRIN2DGRIN3BGRIN1
SCHEMBL22185228 0.74 HRH4 (0.43) IDH1HRH4GRIN2DGRIN3BGRIN1
SCHEMBL18171730 0.74 HRH4 (0.43) IDH1HRH4GRIN2DGRIN3BGRIN1
SCHEMBL17601293 0.73 IDH1 (0.51) IDH1GRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12275715-B2 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2025-04-15 US disclosed
US-20240150319-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2024-05-09 US disclosed
CN-117695280-A Pyridin-2 (1H) -one quinolinone derivatives as mutant isocitrate dehydrogenase inhibitors 福马治疗股份有限公司 2024-03-15 CN disclosed
CN-111909130-B Pyridin-2 (1H) -one quinolinone derivatives as mutant isocitrate dehydrogenase inhibitors 福马治疗股份有限公司 2023-10-31 CN disclosed
US-20230125739-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2023-04-27 US disclosed
US-11498913-B2 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2022-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125739-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH2 IDH1 1/4885HRH4 1574/4885GRIN2D 3038/4885
US-12275715-B2 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors IDH1, IDH3A, IDH2 IDH1 1/4885HRH4 1574/4885GRIN2D 3038/4885
US-11498913-B2 Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors IDH1, IDH3A, IDH2 IDH1 1/4885HRH4 1574/4885GRIN2D 3038/4885
US-20240150319-A1 PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH2 IDH1 1/4885HRH4 1574/4885GRIN2D 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.